Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for …

L Paz-Ares, F de Marinis, M Dediu, M Thomas… - The lancet …, 2012 - thelancet.com
Background Patients with advanced non-squamous non-small-cell lung cancer (NSCLC)
benefit from pemetrexed maintenance therapy after induction therapy with a platinum …
被引用次数：778 相关文章

Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for …

L Paz-Ares, F de Marinis, M Dediu, M Thomas… - Lancet Oncol, 2012 - thelancet.com
Background Patients with advanced non-squamous non-small-cell lung cancer (NSCLC)
benefit from pemetrexed maintenance therapy after induction therapy with a platinum …

[引用][C] Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin …

L Paz-Ares, F de Marinis, M Dediu… - The Lancet …, 2012 - produccioncientifica.ucm.es
Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best
supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous …

Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for …

L Paz-Ares, F de Marinis, M Dediu, M Thomas… - The Lancet …, 2012 - Elsevier
BACKGROUND: Patients with advanced non-squamous non-small-cell lung cancer
(NSCLC) benefit from pemetrexed maintenance therapy after induction therapy with a …

[引用][C] Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin …

L Paz-Ares, F de Marinis, M Dediu, M Thomas… - The Lancet …, 2012 - cir.nii.ac.jp
Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best
supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous …
[PDF] webhost4life.com

[PDF][PDF] Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin …

L Paz-Ares, F de Marinis, M Dediu… - Lancet …, 2012 - mauriciolema.webhost4life.com
Background Patients with advanced non-squamous non-small-cell lung cancer (NSCLC)
benefit from pemetrexed maintenance therapy after induction therapy with a platinum …

Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for …

L Paz-Ares, F de Marinis, M Dediu, M Thomas… - THE LANCET …, 2012 - boa.unimib.it
Background: Patients with advanced non-squamous non-small-cell lung cancer (NSCLC)
benefit from pemetrexed maintenance therapy after induction therapy with a platinum …

Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for …

L Paz-Ares, F de Marinis, M Dediu, M Thomas… - The Lancet …, 2012 - europepmc.org
Background Patients with advanced non-squamous non-small-cell lung cancer (NSCLC)
benefit from pemetrexed maintenance therapy after induction therapy with a platinum …

Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for …

L Paz-Ares, F de Marinis, M Dediu… - The Lancet …, 2012 - pubmed.ncbi.nlm.nih.gov
Background Patients with advanced non-squamous non-small-cell lung cancer (NSCLC)
benefit from pemetrexed maintenance therapy after induction therapy with a platinum …

Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for …

L Paz-Ares, F de Marinis, M Dediu, M Thomas… - The Lancet …, 2012 - infona.pl
Patients with advanced non-squamous non-small-cell lung cancer (NSCLC) benefit from
pemetrexed maintenance therapy after induction therapy with a platinum-containing, non …